Henlius Calls 23 November 2026 EGM to Vote on HLX01 Cap Revision and Board Changes

Bulletin Express11-02

The Board of Shanghai Henlius Biotech, Inc. (Henlius) has convened an Extraordinary General Meeting (EGM) for 2:00 p.m. on Monday, 23 November 2026 at the company’s headquarters in Shanghai.

The agenda comprises three ordinary resolutions: 1. Revision of the annual cap for collaboration arrangements under the HLX01 Agreement, with authority delegated to any director to execute related documents. 2. Appointment of Mr. Zhi Huang as a non-executive director. 3. Appointment of Dr. Huajun Chen as an independent non-executive director.

Voting will be conducted by poll in accordance with Hong Kong Listing Rules. Shareholders recorded on the register as of Monday, 23 November 2026 are entitled to vote; the register will be closed from 18 to 23 November 2026 inclusive. Proxy forms must be lodged no later than 2:00 p.m. on Sunday, 22 November 2026.

Henlius’ current board consists of nine members, led by Chairman Dr. Xingli Wang. The proposed appointments aim to expand non-executive oversight and independent representation while advancing the HLX01 collaboration framework.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment